Steven Coutré

34.4k total citations · 6 hit papers
238 papers, 10.5k citations indexed

About

Steven Coutré is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Steven Coutré has authored 238 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Genetics, 102 papers in Hematology and 91 papers in Pathology and Forensic Medicine. Recurrent topics in Steven Coutré's work include Chronic Lymphocytic Leukemia Research (150 papers), Lymphoma Diagnosis and Treatment (91 papers) and Acute Lymphoblastic Leukemia research (48 papers). Steven Coutré is often cited by papers focused on Chronic Lymphocytic Leukemia Research (150 papers), Lymphoma Diagnosis and Treatment (91 papers) and Acute Lymphoblastic Leukemia research (48 papers). Steven Coutré collaborates with scholars based in United States, United Kingdom and Italy. Steven Coutré's co-authors include Richard R. Furman, Ian W. Flinn, John C. Byrd, Jan A. Burger, Susan O’Brien, Jennifer R. Brown, William G. Wierda, Martin S. Tallman, Nina D. Wagner‐Johnston and Jeffrey A. Jones and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Steven Coutré

235 papers receiving 10.3k citations

Hit Papers

United States Multicenter Study of Arsenic Trioxide in Re... 2001 2026 2009 2017 2001 2015 2014 2019 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
    2001 632 citations Dan Douer, Martin S. Tallman et al. Journal of Clinical Oncology profile →
  2. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
    2015 484 citations John C. Byrd, Richard R. Furman et al. Blood profile →
  3. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
    2014 465 citations John C. Byrd, Steven Coutré et al. Blood profile →
  4. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    2019 312 citations Jan A. Burger, Paul M. Barr et al. profile →
  5. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
    2019 307 citations Susan O’Brien, Paul M. Barr et al. profile →
  6. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 
    2022 146 citations Paul M. Barr, Carolyn Owen et al. Blood Advances profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven Coutré United States 51 6.1k 4.3k 4.2k 3.4k 2.3k 238 10.5k
Jiřı́ Mayer Czechia 42 4.7k 0.8× 2.6k 0.6× 4.0k 1.0× 1.6k 0.5× 1.4k 0.6× 421 8.7k
Alessandra Ferrajoli United States 69 9.3k 1.5× 6.1k 1.4× 7.4k 1.8× 4.1k 1.2× 3.6k 1.6× 527 16.4k
Jonathan E. Kolitz United States 61 6.7k 1.1× 4.0k 0.9× 6.6k 1.6× 5.2k 1.5× 3.7k 1.6× 256 14.4k
Charles Koller United States 65 7.5k 1.2× 4.7k 1.1× 6.8k 1.6× 3.6k 1.1× 3.3k 1.4× 239 15.1k
Eric D. Hsi United States 62 3.5k 0.6× 6.0k 1.4× 2.1k 0.5× 3.2k 0.9× 2.6k 1.1× 405 12.2k
Rajyalakshmi Luthra United States 65 3.6k 0.6× 3.3k 0.8× 4.1k 1.0× 5.0k 1.4× 826 0.4× 308 13.7k
Richard R. Furman United States 51 7.3k 1.2× 7.4k 1.7× 2.3k 0.6× 2.3k 0.7× 3.6k 1.5× 301 11.8k
Christian Thiede Germany 56 2.7k 0.4× 2.0k 0.5× 6.7k 1.6× 3.7k 1.1× 1.6k 0.7× 268 12.1k
Emili Montserrat Spain 66 10.5k 1.7× 9.4k 2.2× 3.8k 0.9× 3.4k 1.0× 5.3k 2.3× 296 16.3k
Bruce D. Cheson United States 37 3.0k 0.5× 5.3k 1.2× 2.9k 0.7× 1.9k 0.5× 1.4k 0.6× 130 9.6k

Countries citing papers authored by Steven Coutré

Since Specialization
Citations

This map shows the geographic impact of Steven Coutré's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Coutré with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Coutré more than expected).

Fields of papers citing papers by Steven Coutré

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Coutré. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Coutré. The network helps show where Steven Coutré may publish in the future.

Co-authorship network of co-authors of Steven Coutré

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Coutré. A scholar is included among the top collaborators of Steven Coutré based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Coutré. Steven Coutré is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Barr, Paul M., Carolyn Owen, Tadeusz Robak, et al.. (2022). Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia . Blood Advances. 6(11). 3440–3450. 146 indexed citations breakdown →
3.
Byrd, John C., Richard R. Furman, Steven Coutré, et al.. (2020). Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clinical Cancer Research. 26(15). 3918–3927. 126 indexed citations
4.
Swords, Ronan, Steven Coutré, Michael B. Maris, et al.. (2018). Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 131(13). 1415–1424. 157 indexed citations
5.
O’Brien, Susan, Peter Hillmen, Steven Coutré, et al.. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 648–657.e15. 63 indexed citations
6.
Barnes, James I., Vasu Divi, Adrian Begaye, et al.. (2018). Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Advances. 2(15). 1946–1956. 38 indexed citations
7.
Jones, Jeffrey A., Anthony R. Mato, Steven Coutré, et al.. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology. 182(4). 504–512. 32 indexed citations
8.
9.
Coutré, Steven, Richard R. Furman, Ian W. Flinn, et al.. (2017). Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research. 23(5). 1149–1155. 47 indexed citations
10.
11.
12.
Pollyea, Daniel A., James L. Zehnder, Steven Coutré, et al.. (2012). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 98(4). 591–596. 46 indexed citations
13.
O’Donnell, Margaret, Jessica K. Altman, Frederick R. Appelbaum, et al.. (2011). Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network. 9(3). 280–317. 53 indexed citations
14.
Muus, Petra, Eric Van Den Neste, Ulrich Duehrsen, et al.. (2007). The clinical benefit of eculizumab is demonstrable in all subpopulations of patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis. 92. 137–138. 1 indexed citations
15.
Nabhan, Chadi, Steven Coutré, & Peter Hillmen. (2006). Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. British Journal of Haematology. 136(3). 379–392. 17 indexed citations
16.
Coutré, Steven & Jason Gotlib. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in Cancer Biology. 14(4). 307–315. 18 indexed citations
17.
Cao, Thai M. & Steven Coutré. (2003). T-cell Prolymphocytic Leukemia: Update and Focus on Alemtuzumab (Campath-1H). Hematology. 8(1). 1–6. 8 indexed citations
18.
Keating, Michael J., Bruno Cazin, Steven Coutré, et al.. (2002). Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. Journal of Clinical Oncology. 20(1). 205–213. 73 indexed citations
19.
Nguyen, Dorothy, et al.. (2002). Cytomegalovirus Viremia During Campath-1H Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia. Clinical Lymphoma. 3(2). 105–110. 55 indexed citations
20.
Lifson, Jeffrey D., Steven Coutré, Erich Huang, & E G Engleman. (1986). Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion.. The Journal of Experimental Medicine. 164(6). 2101–2106. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiřı́ Mayer Breakdown of academic impact, for papers by Alessandra Ferrajoli Breakdown of academic impact, for papers by Jonathan E. Kolitz Breakdown of academic impact, for papers by Charles Koller Breakdown of academic impact, for papers by Eric D. Hsi Breakdown of academic impact, for papers by Rajyalakshmi Luthra Breakdown of academic impact, for papers by Richard R. Furman Breakdown of academic impact, for papers by Christian Thiede Breakdown of academic impact, for papers by Emili Montserrat Breakdown of academic impact, for papers by Bruce D. Cheson
Rankless by CCL
2026